VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 29, 2010) -
NOT FOR DISSEMINATION IN THE UNITED STATES OR TO UNITED STATES PERSONS OR FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
Med BioGene Inc. (TSX VENTURE:MBI) is pleased to announce that it has engaged Kilmer Lucas (www.kilmerlucas.com) to provide MBI with United States and Canadian investor relations and corporate communications services.
With offices in San Francisco and Toronto, Kilmer Lucas is a leading investor relations and corporate communications boutique focused on cross-border emerging healthcare companies. The firm's co-founder and President, Stephen Kilmer, will oversee the services provided to MBI.
Mr. Kilmer has over twenty years industry experience and, prior to founding Kilmer Lucas, was the Vice President of Investor and Public Affairs for OccuLogix Inc., a NASDAQ and Toronto Stock Exchange-listed medical device company. OccuLogix completed a US $101 million IPO, the largest healthcare IPO in Canadian history and the first successful IPO of a non-FDA-approved medical device company on NASDAQ in more than a decade.
For providing services to MBI, Kilmer Lucas will receive an industry-standard monthly fee, plus approved reimbursement of expenditures. MBI also granted to Kilmer Lucas on March 18, 2010 stock options to purchase 250,000 MBI common shares at an exercise price of $0.125 per share, being the closing price of MBI's common shares on the TSX Venture Exchange on such date.
About Med BioGene
MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. For more information, please visit www.medbiogene.com.
Certain statements in this press release contain forward-looking information and statements ("forward-looking statements") under applicable Canadian and United States securities legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward looking statements include, but are not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. These forward-looking statements are only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. MBI's forward-looking statements do not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking statements are qualified in their entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.
This press release is intended for distribution outside the United States only and is not intended for distribution to United States newswire services or dissemination in the United States. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities of MBI in the United States.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.